In the PULSE trial, CCTA following PCI for unprotected left main disease failed to reduce the composite primary endpoint of all-cause death, spontaneous MI, unstable angina, or definite or probable ...

The ACC has released a new Expert Consensus Decision Pathway (ECDP) addressing "10 issues for the clinician in tricuspid regurgitation (TR) evaluation and management." Published in JACC, the ECDP ...

The Global Heart Attack Treatment Initiative (GHATI) is dedicated to collaborating, collecting and sharing data, and utilizing tools to improve acute myocardial infarction (AMI) care for your MI ...

I am so honored to serve as the ACC WIC Leadership Council and Section Chair for 2022 to 2025. I am dedicated to enhancing our profession by engaging, preparing, and promoting women in leadership, ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...

Black Americans suffered nearly 800,000 excess age-adjusted deaths and 24 million excess years of potential life lost due to cardiovascular disease from 2000 to 2022, compared with their White ...

Persistent symptoms after an acute pulmonary embolism (PE) may indicate post-pulmonary embolism syndrome (PPES), a condition affecting up to 50% of patients. The most important consideration in ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...